Views & Analysis Harnessing RWE in rare diseases Ahead of eyeforpharma Philadelphia 2019, Sonal Bhatia, Pfizer’s vice president, North America medical lead, rare disease talked to us about the importance of collaboration and RWE to he
Digital Company profile: Evidera Data disruption and applying ‘enabled intelligence’ to convert the promise shown in clinical trials into real-world success.
Views & Analysis Orphan drugs: overcoming barriers to market access What manufacturers should consider, after successfully overcoming any HTA hurdles, to achieve market access.
Views & Analysis Is the NHS ready to use real-world evidence to treat cancer? Is NHS ready to use real-world data to find new therapies and ways to bring drugs to patients?
Views & Analysis Utilise medtech for optimum care management Medtech companies can provide the tools to empower patients and HCPs.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.